TransMedics Group (NASDAQ:TMDX) Coverage Initiated at Robert W. Baird

Robert W. Baird started coverage on shares of TransMedics Group (NASDAQ:TMDX) in a research report report published on Tuesday morning, Marketbeat reports. The firm issued an outperform rating and a $200.00 target price on the stock.

Several other research firms have also recently issued reports on TMDX. Piper Sandler boosted their target price on TransMedics Group from $170.00 to $180.00 and gave the company an overweight rating in a research note on Thursday, August 1st. Oppenheimer boosted their price objective on shares of TransMedics Group from $125.00 to $200.00 and gave the company an outperform rating in a research report on Thursday, August 1st. Cantor Fitzgerald began coverage on shares of TransMedics Group in a research report on Thursday, June 6th. They issued an overweight rating and a $161.00 target price for the company. Morgan Stanley boosted their price target on shares of TransMedics Group from $104.00 to $145.00 and gave the company an equal weight rating in a research report on Monday, July 15th. Finally, Stephens raised their price objective on shares of TransMedics Group from $151.00 to $178.00 and gave the stock an overweight rating in a report on Friday, August 2nd. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, TransMedics Group currently has a consensus rating of Moderate Buy and an average target price of $174.30.

TransMedics Group Trading Down 2.2 %

NASDAQ:TMDX opened at $156.00 on Tuesday. The firm has a market capitalization of $5.14 billion, a P/E ratio of -458.82 and a beta of 1.99. TransMedics Group has a 52 week low of $36.42 and a 52 week high of $177.37. The company has a quick ratio of 8.48, a current ratio of 9.37 and a debt-to-equity ratio of 2.67. The company has a fifty day moving average of $156.04 and a 200 day moving average of $130.65.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Wednesday, July 31st. The company reported $0.35 earnings per share for the quarter, topping analysts’ consensus estimates of $0.21 by $0.14. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. The company had revenue of $114.30 million during the quarter, compared to analyst estimates of $98.84 million. During the same period in the prior year, the business posted ($0.03) earnings per share. TransMedics Group’s revenue for the quarter was up 117.7% on a year-over-year basis. On average, research analysts predict that TransMedics Group will post 1.23 earnings per share for the current year.

Insider Buying and Selling

In other news, Director James R. Tobin sold 20,000 shares of TransMedics Group stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $159.33, for a total transaction of $3,186,600.00. Following the completion of the transaction, the director now directly owns 173,146 shares in the company, valued at $27,587,352.18. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of the business’s stock in a transaction on Monday, July 15th. The stock was sold at an average price of $145.17, for a total value of $1,252,091.25. Following the sale, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at $8,948,714.31. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director James R. Tobin sold 20,000 shares of the firm’s stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $159.33, for a total value of $3,186,600.00. Following the transaction, the director now owns 173,146 shares of the company’s stock, valued at $27,587,352.18. The disclosure for this sale can be found here. Insiders have sold 61,247 shares of company stock valued at $9,650,880 over the last quarter. Corporate insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

A number of hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in TransMedics Group by 1.3% in the first quarter. Vanguard Group Inc. now owns 1,889,094 shares of the company’s stock worth $139,680,000 after buying an additional 23,979 shares during the last quarter. Driehaus Capital Management LLC increased its position in shares of TransMedics Group by 15.8% during the second quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock valued at $223,832,000 after acquiring an additional 202,867 shares in the last quarter. Eventide Asset Management LLC raised its holdings in TransMedics Group by 7.4% in the 4th quarter. Eventide Asset Management LLC now owns 994,240 shares of the company’s stock worth $78,475,000 after acquiring an additional 68,884 shares during the last quarter. First Light Asset Management LLC lifted its position in TransMedics Group by 22.0% in the 4th quarter. First Light Asset Management LLC now owns 754,317 shares of the company’s stock valued at $59,538,000 after acquiring an additional 136,217 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its stake in TransMedics Group by 3.1% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 730,010 shares of the company’s stock valued at $53,977,000 after purchasing an additional 21,737 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.